August 2010
Worldwide Biotech;Aug2010, Vol. 22 Issue 8, p4
Trade Publication
The article reports that Pain Therapeutics Inc. has announced the changes in its strategic alliance with King Pharmaceuticals Inc. for REMOXY outside the U.S. Pain Therapeutics will take a flat royalty rate of 10% on net sales of REMOXY outside the U.S. and King Pharmaceuticals will make a one-time payment of 5,000,000 U.S. dollars in July 2010.


Related Articles

  • Pain Seeks OK of Harderto-Abuse Oxycodone.  // Bioworld Week;6/16/2008, Vol. 16 Issue 24, p4 

    The article reports on Pain Therapeutics Inc., the first company to develop oxycodone product on the market designed to treat moderate to severe chronic pain. Pain and its partner King Pharmaceuticals Inc. submitted their new drug application to the U.S. Food and Drug Administration (FDA) for...

  • FDA Rejects Pain's and King's Remoxy.  // Bioworld Week;12/15/2008, Vol. 16 Issue 50, p1 

    The article reports on the rejection of Remoxy, a controlled-release formulation of oxycodone from Pain Therapeutics Inc. and King Pharmaceuticals Inc, by the U.S. Food and Drug Administration (FDA). It says that the FDA desires more nonclinical data but has not asked or recommended additional...

  • Pain Therapeutics, Durect Still 'Not Out of the Woods'. Shaffer, Catherine // BioWorld Today;8/20/2013, Vol. 24 Issue 159, p1 

    The article reports on an increase in the stock prices of Pain Therapeutics Inc. and Durect Corp. following the move by Pfizer to begin a clinical trial of Remoxy three months after the former indicated that it might discontinue the oxycodone formulation. Pain Therapeutic licensed Remoxy from...

  • Pain Therapeutics Hits Goals In Remoxy Phase III Trial. Morrison, Trista // BioWorld Today;12/7/2007, Vol. 18 Issue 237, p1 

    The article reports on the primary endpoint achieved by Pain Therapeutics Inc. in its second Phase III trial with Remoxy. President Remi Barbier said the data confirm that abuse-deterrence and effective analgesia can coexist. Remoxy delivers the opioid oxycodone in a gel capsule that is...

  • Pain Therapeutics, King Tumble On FDA's Remoxy Rejection. Young, Donna // BioWorld Today;12/12/2008, Vol. 19 Issue 241, p1 

    This article reports on the decline in the shares of Pain Therapeutics Inc. after receiving a complete response letter from the U.S. Food and Drug Administration (FDA) for Remoxy, a controlled-release formulation of oxycodone. In addition, Pain Therapeutics and its partner King Pharmaceuticals...

  • WORD ON THE STREET. Pyle, Jason; Barbier, Remi // BioWorld Insight;10/28/2013, Vol. 21 Issue 44, p6 

    Several quotations related to cancer treatment, manufacturing issues and proposed rules, are presented by the pharmaceutical industry professionals including Jason Pyle, chief executive officer (CEO) of Triton Algae Innovations Ltd. and Remi Barbier, CEO of Pain Therapeutics Inc.

  • Abuse-resistant painkillers get mixed FDA response. Waters, Hannah // Nature Medicine;Aug2011, Vol. 17 Issue 8, p905 

    The article focuses on the mixed response of the U.S. Food and Drug Administration (FDA) over abuse-resistant painkillers. It states that Oxecta, a new abuse-deterrent formulation of oxycodone that was developed by Pfizer Inc. and Acura Pharmaceuticals Inc. was approved by FDA on June 20, 2011....

  • Tonic in joint venture with Swedish King. Matthews, Sam // New Media Age;8/10/2006, p2 

    This article reports on the joint venture forged by digital design advertising agency Tonic with offline Swedish advertising agency King. The joint venture will be called King@tonic. The first client of the venture is Scandinavian food and retail store ICA. It explains that Tonic has helped in...

  • Mylan Snags King in $4 Bn Deal.  // Chemical Market Reporter;8/2/2004, Vol. 266 Issue 4, p2 

    Reports on the acquisition of King Pharmaceuticals Inc. by Mylan Laboratories Inc. Terms under the deal; Benefits of the agreement for both companies; Significance of the deal for the pharmaceutical industry.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics